Anavex Life Sciences (AVXL) Long-Term Debt Repayments (2014)
Anavex Life Sciences recorded quarterly Long-Term Debt Repayments of $88144.0 in Q4 2014.
Anavex Life Sciences' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $88144.0 for Q4 2014.
- In Q4 2014, Long-Term Debt Repayments changed N/A year-over-year to $88144.0; the TTM figure through Sep 2015 stood at $88144.0 (changed N/A YoY), while the FY2016 annual figure was $34759.0, down 60.57% from the prior year.
- Long-Term Debt Repayments came in at $88144.0 for Q4 2014 at Anavex Life Sciences.
- In the past five years, Long-Term Debt Repayments ranged from a high of $88144.0 in Q4 2014 to a low of $88144.0 in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 88,144.00 |
| Dec 31, 2014 | 88,144.00 |